Search results
Diabetic ketoacidosis (DKA) is a frequent and potentially life-threatening complication of type 1 diabetes. Though preventable and despite advances in monitoring technologies, insulin therapeutics and insulin delivery systems, the rates of both community and hospital acquired DKA remain largely unchanged. Although mortality today is relatively
22 maj 2020 · This is a subcutaneous (SubQ) insulin protocol that replaces insulin drip needs for mild to moderate DKA. Procedures are adapted for COVID-related considerations of minimizing risk to staff while optimizing patient safety and health.
Serum Glucose Reaches 250 mg/dL. Add Dextrose (D51⁄2NS or D5NS*) to IVF @ 150 – 250 mL/h to maintain serum glucose 150 – 200 mg/dL and continue insulin at same rate. Titrate insulin to a minimum 0.1 Units/kg/hr and glucose goal between 150 – 200 mg/dL until ketosis and anion gap resolves.
Transition to adult critical care insulin drip protocol, weaning insulin drip to off as able. h. Discuss conversion to home insulin therapy with rounding Physician.
The protocol aims to safely treat eligible DKA patients with subcutaneous insulin to minimize COVID-19 risks compared to intravenous insulin drips. This document presents a subcutaneous insulin protocol for treating mild to moderate diabetic ketoacidosis (DKA) developed by Montefiore hospital.
intravenous insulin, cbg and ketones monitoring record sheet Guide: Only use for patients on intravenous insulin regimen (use different chart for patients on subcutaneous insulin)
This is a subcutaneous (SC) insulin protocol that replaces the IV insulin infusion needs for mild to moderate DKA, adapted to minimize the risks to staff exposure, use of PPE, while optimizing patient
